PRL-3's Role in AML Treatment with ABT-869 and SAHA
Author Information
Author(s): Zhou Jianbiao, Bi Chonglei, Chng Wee-Joo, Cheong Lip-Lee, Liu Shaw-Cheng, Mahara Sylvia, Tay Kian-Ghee, Zeng Qi, Li Jie, Guo Ke, Tan Cheng Peow Bobby, Yu Hanry, Albert Daniel H., Chen Chien-Shing
Primary Institution: Cancer Science Institute of Singapore, National University of Singapore
Hypothesis
Combining ABT-869, a FLT3 inhibitor, with SAHA, an HDAC inhibitor, will enhance the treatment efficacy in AML by targeting PRL-3 signaling.
Conclusion
The combination of ABT-869 and SAHA significantly improves therapeutic efficacy against AML by downregulating PRL-3, which is implicated in drug resistance.
Supporting Evidence
- Combining ABT-869 and SAHA led to synergistic killing of AML cells with FLT3 mutations.
- PRL-3 was identified in 47% of AML cases but absent in normal bone marrow.
- Downregulation of PRL-3 was linked to enhanced apoptosis in leukemia cells.
Takeaway
This study shows that using two drugs together can work better to kill leukemia cells than using just one, especially by targeting a protein called PRL-3.
Methodology
The study used leukemia cell lines and primary AML cells to assess the effects of ABT-869 and SAHA on cell proliferation and apoptosis through various assays.
Potential Biases
Potential bias due to the involvement of an author from Abbott Laboratories, which provided the ABT-869 compound.
Limitations
The study's findings are based on cell lines and a limited number of primary AML samples, which may not fully represent the broader patient population.
Participant Demographics
The study included primary AML cells from 3 patients with FLT3-ITD mutations and 3 with wild-type FLT3.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website